Skip to main content
TASLY PHARMACEUTICAL GROUP CO.,LTD. logo

TASLY PHARMACEUTICAL GROUP CO.,LTD. — Investor Relations & Filings

Ticker · 600535 ISIN · CNE000001C81 LEI · 300300JB9F71F58FIC88 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,889 across all filing types
Latest filing 2022-03-30 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 600535

About TASLY PHARMACEUTICAL GROUP CO.,LTD.

http://www.tasly.com

Tasly Pharmaceutical Group Co., Ltd. specializes in the research, development, and production of modern Traditional Chinese Medicine (TCM), biological products, and chemical pharmaceuticals. The company is primarily known for its flagship cardiovascular treatment, Compound Danshen Dripping Pills, which represents a significant advancement in the modernization and standardization of herbal medicine. Its therapeutic portfolio covers cardiovascular, cerebrovascular, digestive, and metabolic diseases, as well as oncology. Tasly utilizes high-tech manufacturing processes and maintains a strong focus on R&D to bridge traditional therapies with modern clinical standards. The organization also explores digital health solutions and innovative drug delivery systems to enhance its comprehensive healthcare offerings.

Recent filings

Filing Released Lang Actions
天士力关于公司2021年度主要经营数据的公告
Regulatory Filings Classification · 95% confidence The document is titled as an announcement regarding the company's main operating data for the year 2021. It contains detailed financial data such as revenue, cost, and gross margin by industry, treatment area, product, and region for the fiscal year 2021. The document is relatively short (3497 characters) and is presented as a disclosure or announcement rather than a full annual report. It does not contain comprehensive financial statements or management discussion and analysis typical of a full Annual Report (10-K). Instead, it appears to be a regulatory announcement of key operating data for the year, consistent with a Regulatory Filing (RNS) category, which is a fallback for miscellaneous regulatory disclosures that do not fit other categories. There is no indication that this is a full Annual Report, Audit Report, or Earnings Release. It is not a report publication announcement since it contains substantive data rather than just a notice of report availability.
2022-03-30 Chinese
天士力关于召开2021年年度股东大会的通知
AGM Information Classification · 95% confidence The document is a notice about the convening of the 2021 Annual General Meeting (AGM) of TianShiLi Pharmaceutical Group Co., Ltd. It includes details such as the date, voting methods, meeting agenda, and proxy authorization form. The document does not contain the actual annual report or financial statements but rather the announcement and procedural information related to the AGM. The document length is 3202 characters, which is relatively short and consistent with a meeting notice rather than a full report. Therefore, it fits the category of AGM Information (AGM-R).
2022-03-30 Chinese
天士力2021年度独立董事述职报告
Board/Management Information Classification · 95% confidence The document is titled '2021年度独立董事述职报告' which translates to '2021 Annual Independent Directors' Report'. It is a detailed report by the independent directors of the company about their duties, attendance, opinions on company matters, and overall evaluation for the year 2021. The content includes descriptions of board meetings, committee meetings, related party transactions, internal controls, and other governance matters. It is not a financial report like an annual or interim report, nor is it a regulatory filing or announcement. It is a management-related report focusing on the independent directors' activities and governance oversight. This fits best under the category of Board/Management Information (MANG), which covers announcements of changes or reports related to the company's board or senior management. The document is substantive and not a brief announcement or certification, so it is not RNS or RPA. Therefore, the classification is MANG with high confidence.
2022-03-30 Chinese
独立董事关于公司与关联方资金往来以及对外担保情况的专项说明及独立意见
Board/Management Information Classification · 85% confidence The document is a special statement and independent opinion from the independent directors of TianShiLi Pharmaceutical Group Co., Ltd. regarding the company's related party transactions and external guarantees for the fiscal year 2021. It references compliance with regulatory notices about related party transactions and guarantees, and provides an independent directors' opinion on the legality and appropriateness of guarantees provided. The document is focused on governance and compliance matters related to financial guarantees and related party dealings, rather than presenting full financial statements or audit results. It is not a full audit report but a governance-related statement by independent directors. Therefore, it fits best under Board/Management Information (MANG), which includes announcements related to board or senior management matters, including independent directors' opinions and governance-related disclosures.
2022-03-30 Chinese
天士力2021年度利润分配预案-0330
Notice of Dividend Amount Classification · 95% confidence The document is a profit distribution plan for the year 2021 by TianShiLi Pharmaceutical Group Co., Ltd. It details the proposed cash dividend per share, total dividend amount, share repurchase information, and the board's approval process. It includes specific dividend ratios, dates, and references to shareholder meetings for approval. The document is an announcement of the dividend amount and related details, not the full annual report or financial statements. It fits the definition of a Notice of Dividend Amount (DIV) as it announces dividend amounts, payment dates, and details for shareholders.
2022-03-30 Chinese
天士力关于2022年度预计发生的日常经营性关联交易的公告
Regulatory Filings Classification · 95% confidence The document is a detailed announcement from TianShiLi Pharmaceutical Group Co., Ltd. regarding the expected daily related-party transactions for the year 2022. It includes extensive tables of related-party transaction amounts, descriptions of the related parties, their relationships, business scopes, financial data, and the nature and pricing policies of the transactions. The document is an official disclosure about ongoing and expected related-party transactions, which is a regulatory requirement for listed companies to inform shareholders and the market about such transactions. It is not a financial report like an annual or interim report, nor is it a management discussion or earnings release. It is also not a voting result, board change, or legal proceeding. The document is a regulatory announcement about related-party transactions, which fits best under the category of Regulatory Filings (RNS) as it is a general regulatory announcement that does not fit other specific categories. The document length is over 13,000 characters, so it is not a brief report publication announcement. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2022-03-30 Chinese

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.